{
    "clinical_study": {
        "@rank": "74056", 
        "arm_group": [
            {
                "arm_group_label": "HMD-SPIRE Treatment 1", 
                "arm_group_type": "Experimental", 
                "description": "4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart"
            }, 
            {
                "arm_group_label": "HDM-SPIRE Treatment 2", 
                "arm_group_type": "Experimental", 
                "description": "4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart"
            }, 
            {
                "arm_group_label": "HDM-SPIRE Treatment 3", 
                "arm_group_type": "Experimental", 
                "description": "4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "8 x placebo 4 weeks apart"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the treatment effect of three treatment regimens of\n      HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue\n      medication usage, Quality of Life and Sleep Quality"
        }, 
        "brief_title": "Phase II HDM-SPIRE Safety and Efficacy Study", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rhinoconjunctivitis", 
        "condition_browse": {
            "mesh_term": "Conjunctivitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged 18-65 years.\n\n          -  Moderate to severe rhinoconjunctivitis on exposure to HDM for at least 1 years.\n\n          -  Mean TRSS \u226510\n\n          -  Positive skin prick test to Der p and Der f.\n\n          -  Dep p and Der f specific IgE \u22650.7 kU/L\n\n        Exclusion Criteria:\n\n          -  Diagnosis of asthma requiringGlobal Initiative for Asthma (GINA) Step 3\n             (www.ginasthma.org)or higher treatment\n\n          -  FEV1 <80% of predicted.\n\n          -  Clinically significant confounding symptoms of allergy to seasonal allergens during\n             the final evaluation period.\n\n          -  Significant symptoms of another clinically relevant illness that is likely to affect\n             scoring of rhinoconjunctivitis symptoms.\n\n          -  Clinically relevant abnormalities detected on physical examination.\n\n          -  History of severe drug allergy, severe angioedema or anaphylactic reaction to food."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "660", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02150343", 
            "org_study_id": "TH005"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HMD-SPIRE Treatment 1", 
                    "HDM-SPIRE Treatment 2", 
                    "HDM-SPIRE Treatment 3"
                ], 
                "description": "1 dose every 4 weeks", 
                "intervention_name": "HDM-SPIRE", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "HMD-SPIRE Treatment 1", 
                    "HDM-SPIRE Treatment 3", 
                    "Placebo"
                ], 
                "description": "1 dose every 4 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cat allergy", 
            "Rhinoconjunctivitis"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Germany: Paul-Ehrlich-Institut", 
                "Spain: Spanish Agency of Medicines", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measurement of subject allergy symptoms (e.g. sneezing, watery eyes) and use of allergy medication", 
            "measure": "Combined score of symptoms and allergy medication", 
            "safety_issue": "No", 
            "time_frame": "up to 52 weeks after randomisation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02150343"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks after randomisation"
            }, 
            {
                "measure": "Sleep Quality", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks after randomisation"
            }, 
            {
                "measure": "Incidence and frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 52 weeks after randomisations"
            }
        ], 
        "source": "Circassia Limited", 
        "sponsors": {
            "collaborator": {
                "agency": "Quintiles", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Circassia Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}